Saturday 17 October 2026
Export CYTOF’s income statement to Excel — free account
Altamira Therapeutics Ltd.
CYTOF Healthcare Biotechnology
Altamira Therapeutics Ltd.’s revenue for fiscal 2022 (year ended December 2022) was $320,300.00.
0.09
0.00
0.00%
Follow CYTOF
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 67,200.00 | 30,400.00 | 1,840.00 | 520.00 | 260.00 | 484.00 | 79.02 | 1.88 | 0.07 | 0.05 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | 636,800.00 | 111,200.00 | 52,000.00 | 4,360.00 | 2,640.00 | 2,500.00 | 860.00 | 119.40 | 3.60 | 0.20 | |||||
| People | |||||||||||||||
| People | Employees | 24 | 24 | 11 | 12 | 9 | 17 | 18 | 12 | 13 | — | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | — | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | 0 | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (3,407.01) | (372.40) | — | — | — | |||||
| EBT | (31) | (25) | (12) | (7) | (9) | (19) | (28) | (8) | (8) | (3) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (27,185.84) | (8,682.49) | 0.00 | 0.00 | 0.00 | |||||
| Net income | (31) | (25) | (12) | (7) | (9) | (19) | (28) | (4) | (8) | (3) | |||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.11 | 7.04 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (72,000.00) | (45,520.00) | (5,920.00) | (920.00) | (580.00) | (572.00) | (610.60) | (8.77) | (2.70) | (0.55) | |||||
| Cash flow | (74,760.75) | (49,343.00) | (6,764.30) | (1,157.26) | (344.40) | (451.94) | (199.98) | (26.09) | (2.16) | (0.37) | |||||
| Capex | (620.25) | (311.00) | (931.90) | (416.19) | (164.63) | (109.94) | (49.35) | 0.00 | (0.04) | 0.01 | |||||
| Free cash flow | (75,381.00) | (49,654.00) | (7,696.20) | (1,573.45) | (509.03) | (561.88) | (249.33) | (26.09) | (2.20) | (0.37) | |||||
| Book value | 35,898.00 | (4,395.00) | 1,865.70 | 832.25 | 1,192.45 | 419.94 | (191.50) | 15.63 | 2.32 | 0.57 | |||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 5 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | — | — | — | ||||
| P/S | — | — | — | — | — | 0.00 | 0.00 | — | — | — | |||||
| P/B | — | — | — | — | — | 0.10 | 0.03 | — | — | — | |||||
| EV/Sales | — | — | — | — | — | 0.00 | 0.00 | — | — | — | |||||
| EV/FCF | — | — | — | — | — | (0.21) | (0.32) | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (30) | (25) | (14) | (8) | (5) | (15) | (9) | (13) | (6) | (2) | ||||
| Capex | 0 | 0 | (2) | (3) | (2) | (4) | (2) | — | 0 | 0 | |||||
| Free cash flow | (30) | (25) | (15) | (11) | (8) | (19) | (11) | (13) | (6) | (2) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 25 | 6 | 2 | 0 | 9 | (1) | (12) | 0 | 0 | (4) | ||||
| Total debt | 13 | 10 | 1 | — | 1 | 0 | 6 | — | — | 1 | |||||
| Net debt | (20) | (5) | (4) | (2) | (11) | (1) | 6 | (1) | (1) | 1 | |||||
| Shareholders’ equity | 14 | (2) | 4 | 6 | 18 | 14 | (9) | 8 | 7 | 3 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (69.89) | (91.34) | (83.32) | (68.87) | (55.58) | (88.92) | (204.28) | (54.69) | (95.05) | (35.73) | ||||
| ROIC | 0.00 | 0.00 | 0.00 | (102.37) | (54.71) | (90.30) | 0.00 | (61.90) | (76.92) | (66.25) | |||||
| ROE | (105.24) | (407.96) | (1,532.55) | (136.13) | (73.00) | (119.71) | (1,071.90) | 829.81 | (118.79) | (61.66) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022 · latest quarter Jan 0001 · fundamentals updated 14 Oct 2026
Charts ten years each
Altamira Therapeutics Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| MLEC Moolec Science SA | $1.4M | — (loss-making) | — (loss-making) | +948.39% (above 0%: growing) | n/m | +4.48% (above 0%: growing) | (25.52%) | (77.92%) | Compare |
| PTIX Atrinsic Inc. | $1.3M | 0.3× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SPRC SciSparc Ltd. | $1.2M | — (loss-making) | 7.9× | — | n/m | +14.95% (above 0%: growing) | 35.75% | 0.00% | Compare |
| CYTOF Altamira Therapeutics Ltd. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +85.35% (above 0%: growing) | (157.79%) | 0.00% | |
| BBLG Bone Biologics Corp. | $1.1M | — (loss-making) | — | — | n/m | −12.97% (below 0%: shrinking) | — | 0.00% | Compare |
| BPTH Bio-Path Holdings, Inc. | $1.1M | — (loss-making) | — (loss-making) | — | n/m | +98.68% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CRIS Curis, Inc. | $1.1M | — (loss-making) | — (loss-making) | −65.98% (below 0%: shrinking) | n/m | −20.44% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| MNTRQ 9 Meters Biopharma, Inc. | $1.0M | — (loss-making) | — | −25.99% (below 0%: shrinking) | n/m | +0.01% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ZVSA ZyVersa Therapeutics, Inc. | $970.0K | — (loss-making) | — | — | n/m | +54.91% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $1.1M | — | — | +4.16% | — | +9.72% | 0.00% | 0.00% |
Altamira Therapeutics Ltd. (CYTOF) key facts
- Altamira Therapeutics Ltd. (CYTOF) is a Biotechnology company in the Healthcare sector.
- Altamira Therapeutics Ltd.’s revenue for fiscal 2022 (year ended December 2022) was $320,300.00.
- As of October 16, 2026, CYTOF traded at $0.09, a market capitalization of $1.1 million.
- Return on equity was −61.7% and debt-to-equity 0.11.
- Its Altman Z-score is −60.32 (distress zone) for fiscal 2022.